Intrexon | XON - Ordinary Share Capital


Intrexon reported $0 in Ordinary Share Capital for its fiscal quarter ending in June of 2024.





Ordinary Share Capital Change Date
Agenus USD 38.52M 3.2M Mar/2026
Alaunos Therapeutics USD 2.38M 172K Mar/2026
Amgen USD 541M 1000K Jun/2026
Anika Therapeutics USD 13.89M 532K Dec/2025
Arrowhead Research USD 141.14M 564K Jun/2026
AstraZeneca USD 1.55B 44K Jun/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Gilead Sciences USD 1.24B 1000K Jun/2026
GlaxoSmithKline GBP 4.08B 20.6M Jun/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Incyte USD 200.98M 1.03M Jun/2026
Intrexon USD 0 0 Jun/2024
Karyopharm Therapeutics USD 22.54M 4.23M Mar/2026
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
MacroGenics USD 63.56M 241K Mar/2026
MannKind USD 309.91M 1M Jun/2026
Merck USD 2.47B 4.93M Mar/2026
Novartis USD 1.9B 7.38M Jun/2026
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Roche Holding CHF 796.77M 1.15M Jun/2026
Thermo Fisher Scientific USD 371.62M 1000 Jun/2026
Veracyte USD 79.79M 1000 Jun/2026
Xencor USD 74.33M 265K Jun/2026